Protalix, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ram Selvaraju has given his Buy rating due to a combination of factors tied to Elfabrio’s regulatory and commercial momentum. He highlights the timely European Commission approval of the once‑monthly Elfabrio dosing regimen for stable Fabry patients, which is supported by long‑term clinical data and robust pharmacokinetic modeling, and sees this more convenient schedule as a key differentiator versus rival enzyme replacement therapies.
Selvaraju also underscores the financial uplift from Protalix’s collaboration with Chiesi, including a $25M European milestone that is embedded in both management guidance and his 2026 revenue estimate, alongside growing Elfabrio royalties and steady Elelyso contributions. Together with improving earnings projections and the potential for U.S. adoption of the monthly regimen, these drivers support his view that Protalix’s shares remain undervalued relative to their 12‑month upside potential.